Recent Updates
Recently added Catalysts
URGN Neutral Sentiment

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Wednesday, April 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: UroGen Pharma Ltd. announced it will report its financial results for the first quarter of 2026 on May 6th, 2026, before the stock market opens. A subsequent audio webcast and conference call will take place at 10:00 AM Eastern Time. Investors will have access to a live stream and a replay for approximately 30 days. This event underscores UroGen's ongoing activities in the biotech sector.
Price reaction · baseline $24.12 (2026-04-28 close) · hit after-hours · clean, no other URGN news in the window
day 0 close · peak
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • UroGen Pharma is preparing to report its first quarter 2026 financial results, indicating ongoing business activity.
  • The company holds a live audio webcast for its financial results, promoting transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+188%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
UGN-104
Phase 3 · Upper Urinary Tract Urothelial Carcinoma

Full Press Release Details

PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.

Frequently Asked Questions

When will UroGen Pharma report its Q1 2026 financial results?

UroGen Pharma will report its Q1 2026 financial results on May 6, 2026.

What time is the UroGen earnings conference call?

The earnings conference call is scheduled for 10:00 AM Eastern Time.

How can I access the UroGen earnings webcast?

The earnings webcast can be accessed on UroGen’s Investor Relations website.

Will a replay of the UroGen conference call be available?

Yes, a replay will be available for about 30 days after the call.

Who to contact for Investor Relations at UroGen?

Contact Vincent Perrone at vincent.perrone@urogen.com or call 609-460-3588 ext. 1093.

ShareAdd on Google
Tags: URGN Viatris Investor Conferences Healthcare UroGen Pharma financial results Q1 2026 biotech earnings call
Last updated: Apr 29, 2026

Biotech snapshot

Cash runway
$109M liquidity · $11M/mo burn
~9 mo
Medium dilution risk
Lead asset
UGN-104Phase 3
Upper Urinary Tract Urothelial Carcinoma →

Catalyst track record

+188%
best trade around URGN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for URGN.

See every catalyst's timing & PoA →